In the rapidly evolving landscape of human genetics, the bottleneck has shifted. While next-generation sequencing technologies now allow researchers to identify genetic variants with unprecedented speed, the ability to interpret these variants—to determine whether a specific mutation is the "smoking gun" behind a clinical condition—has lagged behind.
Dr. Hyung-lok Chung, an Assistant Professor at the Houston Methodist Research Institute and Weill Cornell Medical College, is working to close this gap. In a recent study published in Human Genetics and Genomics Advances, Dr. Chung and his colleagues provide a roadmap for functional validation, specifically addressing the role of MARK2 variants in neurodevelopmental disorders (NDD). By leveraging the humble fruit fly (Drosophila) as a high-throughput laboratory, the team has turned a challenging diagnostic uncertainty into a clear, actionable clinical framework.
Main Facts: The MARK2 Breakthrough
The research, titled "Loss-of-Function Variants in MARK2 Cause Neurodevelopmental Disorder," centers on a gene previously associated with biological signaling pathways but poorly understood in the context of human clinical presentation.
Through a rigorous multi-tissue analysis in Drosophila, Dr. Chung’s team categorized eight specific MARK2 variants identified in patients. The results were granular:
- Truncating variants were classified as clear "loss-of-function."
- Most missense variants were identified as "hypomorphic," meaning they partially reduced the gene’s function.
- One variant behaved identically to the "wild-type," or normal gene, suggesting it was not pathogenic.
This classification system provides clinicians with the necessary evidence to move beyond a "Variant of Uncertain Significance" (VUS) label, offering families a more definitive genetic diagnosis and a clearer understanding of the underlying biology of their condition.
Chronology: From Collaboration to Classification
The genesis of this project was rooted in a long-standing collaborative effort between Dr. Hyung-lok Chung and Dr. Wendy K. Chung, a prominent expert in clinical genetics.
"We have been working together on a series of neurodevelopmental disease genes," explains Dr. Chung. "Her team handles patient ascertainment and genomic analysis, while our lab contributes Drosophila-based functional genomics."
The project hit a notable hurdle midway through development. Just as the team was refining their data, another research group published a case series on MARK2 in the American Journal of Human Genetics (AJHG). For many young investigators, the sudden publication of a similar study could be discouraging. However, Dr. Chung viewed it differently.
"That was a frustrating moment," he admits. "But I felt that good science doesn’t lose its value just because someone else is working in the same area." Recognizing that the clinical report in AJHG lacked the deep-dive functional validation his team was conducting, they pushed forward. The result was a comprehensive, in vivo classification study that complemented—rather than duplicated—the existing literature.
Supporting Data: The Power of Drosophila
The core of the study’s success lies in the versatility of the Drosophila model. To create a "humanized" fly, the team introduced human MARK2 variants into the flies to observe the phenotypic impact.
Each variant was put through a rigorous gauntlet of assays:
- Viability: Does the variant impact the survival rate of the organism?
- Lifespan: Does the gene mutation cause premature mortality?
- Protein Expression: How does the variant alter the stability or levels of the MARK2 protein?
- Wing Patterning: A highly sensitive developmental marker in flies that reveals defects in signaling pathways.
By observing these traits, the researchers built a comprehensive "functional picture" of each variant. This scalable platform serves as a prototype for future research, demonstrating that Drosophila can be used to process the massive backlog of VUSs currently clogging clinical diagnostic pipelines.
Implications for the Future of Clinical Genetics
The impact of this work extends far beyond the MARK2 gene. As genomic sequencing becomes a standard part of pediatric care, the number of variants identified outpaces our ability to understand them.
Bridging the Gap for Families
For families living with undiagnosed or poorly understood neurodevelopmental disorders, this research offers more than just a name for their condition. It offers a path to clinical counseling. As Dr. Chung notes, "A genetic diagnosis is the first step, but understanding what a variant actually does to protein function and brain development is what helps clinicians counsel families and think about next steps."
A Model for Future Studies
The study aims to establish MARK2 as a well-characterized NDD-associated gene, providing a template for how researchers should approach other candidate genes. Dr. Chung’s team hopes that their classification framework will eventually inform the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) criteria for variant interpretation, potentially standardizing how these variants are handled in clinical labs worldwide.
The Rise of Functional Genomics Cores
To ensure this methodology reaches the wider community, Dr. Chung has launched the Houston Methodist Drosophila Functional Genomics Core. This facility is specifically designed to bridge the gap between bench science and clinical practice. "If you have variants of uncertain significance and are unsure how to begin functional studies, feel free to reach out," he invites.
The Challenges of the Independent Investigator
Dr. Chung’s journey also highlights the systemic hurdles faced by early-career researchers. Transitioning from a postdoctoral fellow to an independent investigator is described by Chung as a daunting shift.
"Securing grant funding as a new PI takes a lot of effort—writing proposals, going through study sections, dealing with rejections, all while trying to build a lab at the same time," he says. The administrative burden—budgets, compliance, and mentoring—often competes with the intellectual time required for innovation.
Despite these pressures, he credits the supportive infrastructure at the Houston Methodist Research Institute and the Department of Neurology for his success. He emphasizes that for young scientists, the ability to prioritize projects is a learned survival skill. "Saying ‘not yet’ to a good idea is sometimes just as important as saying ‘yes’ to the right one."
Synthesis: Connecting Rare and Common Diseases
Looking forward, Dr. Chung is optimistic about the convergence of different areas of genetics. He points to the recent surge in large-scale whole-genome sequencing studies that are beginning to identify rare coding variants linked to common neurodegenerative conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis.
Historically, these diseases were studied through Genome-Wide Association Studies (GWAS) that focused on non-coding regions, making it difficult to identify specific causative genes. Now, by finding rare variants that contribute to common disease risk, researchers are beginning to bridge the gap between "rare Mendelian" and "common" disease worlds.
"It is a good time to be in this field," Dr. Chung concludes. "The tools and data are finally catching up to the questions we have been asking for years." By combining the precision of functional genomics with the scale of modern sequencing, scientists like Dr. Chung are not just reading the genetic code—they are finally beginning to understand how to translate it for the benefit of patients.
About the Author
